Jury rules in favour of Kemin in lutein patent case
chemical composition and production process of lutein, in a trial
in Des Moines, Iowa, against Pigmentos Vegetales del Centro.
"We are very pleased that the jury has rendered a favorable verdict finding Kemin's core lutein patents valid and we will continue to vigorously defend our US and international lutein patents," said the company in a statement after the hearing.
Lutein, which cannot be made by the body, helps protect eyes by depositing in the macula where it filters out harmful blue light, stopping it from reaching and damaging the sensitive back tissue of the retina. In the western world the average lutein intake is just 2mg per day, compared to the recommended 6mg daily, according to Kemin.
A recent trial suggested that Lutein supplements may be even more beneficial than previously thought. Lutain has already been shown to fortify the macular layer in the eye and is thought to protect against age-related blindness. According to a small trial, it also appears to increase macular pigment in people at earlier stages of age-related macular degeneration (AMD).
The findings suggest that a much larger group of at-risk individuals than previously thought may gain some benefit from taking lutein supplements. Age-related macular degeneration is the leading cause of blindness in the western world, affecting an estimated 30 million people worldwide. This number is expected to double by 2030. But Ian Murray, lead researcher on the new trial published in the July issue of Experimental Eye Research (79, pp21-27), says that about 20 per cent of individuals over the age of 65 have the early signs (changes in retinal cell pigmentation) of the disease, even though many may not know about it.
Dr Murray and colleagues from the Department of Optometry and Neuroscience at the University of Manchester in the UK evaluated the effects of a lutein esters supplement over a period of 18-20 weeks, in seven patients with early stages of the disease (age-related maculopathy) and six age-matched controls.
Macular pigment density and levels of lutein in blood plasma were measured at regular intervals throughout the study. Both increased significantly, and to the same extent in the controls and in the ARM patients, providing evidence that the macula can accumulate lutein, not only in healthy eyes but in those with the early stages of AMD.
The findings that diseased eyes can also take up extra lutein have also been demonstrated in a recent study by US researchers who found that AMD patients who took lutein supplements could reverse some of the symptoms of the disease. They experienced improvements in glare recovery, contrast sensitivity and visual acuity, compared with patients taking the placebo. Patients also experienced a 50 per cent increase in macular pigment density relative to those on placebo.
Dr Murray said he was "excited by the prospect that a simple addition to the diet may impede the progress of the disease and prevent others who are at risk experiencing such problems. Right now, dietary intervention is the only hope for most of them".
